NEWS


09/10/2018

“THE PHARMACEUTICAL INDUSTRY DEDICATES MANY RESOURCES TO INFLUENCE THE DECISIONS OF PUBLIC INSTITIONS”

We spoke with Ancel-la Santos, the Policy Advisor of Health Action International, an NGO working on the European level to improve the affordability and rational use of drugs. Ancel-la coordinates political advocacy […]
19/09/2018

WE COLLABORATED WITH THE BALEARIC GOVERNMENT TO IMPROVE DRUG POLICIES

This week we signed a collaboration agreement with the Health Service of the Balearic Islands to implement public policies on transparency and impartiality in the rendering of health activities. This is the first […]
17/04/2018

THE PHARMACEUTICAL INDUSTRY BENEFITS FROM CANCER DRUGS DEVELOPED WITH PUBLIC INVESTMENTS

Cancer treatments are among the highest-priced and generate the most profit for the pharmaceutical industry. However, there is significant public investment in the research phases and the clinical trials of many these […]
14/02/2018

Letter to the minister of health for a new funding model for high-priced medicines

Dear Mrs. Minister:   These days the press has been speaking of the launch of a new funding model for drugs with high economic impact for rare diseases as well as oncology. […]
08/02/2018

Treatments for 400 million euros: An unsustainable drug funding model

The Ministry of Health has announced this week the launch of a new model of financing medicines of high economic and health impact aimed at new therapies for rare diseases and cancer. […]
29/11/2017

It’s not Healthy asks the government to eliminate the agreements that benefit pharmaceuticals and debilitate the Autonomous communities

This week, through communication mediums, we became aware that the government obligates the autonomous communities to solicit financial support from the Autonomous Liquidation Fund (ALF) and sign an agreement that guarantees minimum annual […]
15/11/2017

IT’S NOT HEALTHY ASKS GILEAD AND NOVARTIS WHY THEIR NEW TREATMENTS COST 400 MILLION DOLLARS

Surgery, chemotherapy and radiotherapy have always formed the therapeutic arsenal to combat different types of cancer. However, in the last decade, a new type of treatment that begins to position itself as […]
17/03/2017

Organizations from 17 European countries oppose a sofosbuvir patent

30 non-governmental and civil society organizations from 17 European countries have submitted a new opposition this week to the patent of Sofosvbir, the drug that cures Hepatitis C. The resource is based […]
01/02/2017

Our health is at stake

Today many of the medicines that enter the market, such as new cancer or Hepatitis C treatments, reach exorbitant and unjustified prices, which have made the diseases profitable businesses. Our public health […]
13/12/2016

Antibiotic Resistance: Bayonets against tele-directed rockets

Antibiotic resistance is an issue that increasingly threatens our ability to treat infectious diseases and has jeopardized progress in global health in recent decades, due to the abuse and misuse of antibiotics […]
03/12/2016

ALLIANCE IT’S NOT HEALTHY FLOODS THE INTERNET WITH A CAMPAIGN OF CITIZEN PARTICIPATION, DAYS AFTER THE POLITICAL DEBATE FOR A CHANGE IN THE MEDICAL INNOVATION MODEL

3 de diciembre, Madrid.   Un selfie con una tirita y una petición a los partidos por el acceso universal a los medicamentos en redes sociales son los elementos de la nueva […]
28/11/2016

The terms that justify the use of the patents to encourage innovation are not known today

Vincenzo Pavone is a researcher at the Higher Council for Scientific Research, member of the Science and Democracy Network and founder of the Network for Social Studies of Science and Technology (RED EsCTS). We spoke to […]